IFIH1 and pneumocystosis: Our previous study showed that compared to the survival group, there were more patients with anti-MDA5+ in non-survival group (81.5% vs. 45.0%, p = 0.009) and anti-MDA5+ was one of the independent risk factors for IIM-PJP patients (HR = 3.54, p = 0.016, 95% CI: 1.27–9.89) [25].